Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the yearEli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.[Collection]

Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.https://www.cnbc.com/2023/07/17/alzheimers-eli-lilly-expects-fda-decision-on-donanemab-by-year-end.html